Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) EPS (Weighted Average and Diluted) (2017 - 2026)

Champions Oncology has reported EPS (Weighted Average and Diluted) over the past 14 years, most recently at -$0.02 for Q1 2026.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.02 for Q1 2026, down 106.45% from a year ago — trailing twelve months through Jan 2026 was -$0.16 (down 136.36% YoY), and the annual figure for FY2025 was $0.33, up 161.11%.
  • EPS (Weighted Average and Diluted) for Q1 2026 was -$0.02 at Champions Oncology, down from $0.02 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CSBR hit a ceiling of $0.31 in Q1 2025 and a floor of -$0.19 in Q2 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.02 (2022), compared with a mean of -$0.04.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 12576.4% in 2023 and later soared 263.16% in 2025.
  • Champions Oncology's EPS (Weighted Average and Diluted) stood at -$0.0 in 2022, then crashed by 12576.4% to -$0.15 in 2023, then surged by 133.33% to $0.05 in 2024, then plummeted by 60.0% to $0.02 in 2025, then tumbled by 200.0% to -$0.02 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.02 (Q1 2026), $0.02 (Q4 2025), and -$0.03 (Q3 2025) per Business Quant data.